Skip to content

US · PRCT · MEDICAL - DEVICES

PROCEPT BioRobotics Corporation (PRCT) intrinsic value and stock valuation

$24.70as of 2026-11-21 · Mkt cap 1.1B

Data updated · price as of 2026-11-21

Fairly valuedIC value is within 20% of the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

PROCEPT BioRobotics Corporation DCF and intrinsic value

InvestorsCraft values PRCT with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from PRCT’s statements →

PROCEPT BioRobotics Corporation Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Devices San Jose, CA 95134 procept-biorobotics.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$308.1M+109% 5y CAGRd
20192025
Net income
-$-95.57M
20192025
Free cash flow
-$-58.34M
20192025
Total equity
$365.9M+43.1% 5y CAGRd
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$308.1M$224.5M$136.2M$75M$34.5M
Operating income-$-103.86M-$-96.61M-$-109.17M-$-80.72M-$-54.16M
Net income-$-95.57M-$-91.41M-$-105.9M-$-87.15M-$-59.85M
EPSd-$-1.72M-$-1.75M-$-2.24M-$-1.96M-$-1.37M
Operating cash flow-$-48.98M-$-99.21M-$-108M-$-80.38M-$-57.33M
Capital expenditure-$-9.36M-$-4.41M-$-25.21M-$-2.65M-$-590K
Free cash flow-$-58.34M-$-103.62M-$-133.21M-$-83.03M-$-57.93M
Total assets$508.1M$534M$404.7M$309.3M$337M
Total debt$78.5M$80.3M$79.2M$77.3M$54.1M
Net debt-$-208.02M-$-253.47M-$-178.02M-$-145.32M-$-250.22M
Total equity$365.9M$402.2M$280.8M$197.1M$267.1M
Cash and short-term investments$286.5M$333.7M$257.2M$222.6M$304.3M
Income statement
20252024202320222021
Revenue$308.1M$224.5M$136.2M$75M$34.5M
Cost of revenue$111.8M$87.4M$65.1M$37.9M$18.6M
Gross profit$196.2M$137.1M$71.1M$37.1M$15.9M
Research and development expenses$71.3M$62.3M$48.5M$29M$19M
Selling, general and administrative expenses$228.8M$171.4M$131.8M$88.8M$51M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$300.1M$233.7M$180.2M$117.8M$70M
Cost and expenses$411.9M$321.1M$245.4M$155.7M$88.6M
Interest income$12.2M$10.9M$7.55M$2.5M$80K
Interest expense$3.59M$4.18M$4M$5.18M$5.81M
Depreciation and amortization$6.39M$5.23M$3.81M$2.84M$3.32M
Ebitda-$-85.41M-$-82M-$-98.09M-$-79.13M-$-50.72M
Operating income-$-103.86M-$-96.61M-$-109.17M-$-80.72M-$-54.16M
Total other income/expenses, net$8.48M$5.2M$3.27M-$-6.43M-$-5.69M
Income before tax-$-95.38M-$-91.41M-$-105.9M-$-87.15M-$-59.85M
Income tax expense$190K$0.00$0.00$0.00$0.00
Net income-$-95.57M-$-91.41M-$-105.9M-$-87.15M-$-59.85M
Weighted average shares outstanding$55.5M$52.1M$47.3M$44.4M$43.7M
Weighted average diluted shares outstanding$55.5M$52.1M$47.3M$44.4M$43.7M
Balance sheet
20252024202320222021
Cash and short-term investments$286.5M$333.7M$257.2M$222.6M$304.3M
Net receivables$83.5M$83.5M$48.4M$15.3M$4.46M
Inventory$70.7M$56.2M$39.8M$28.5M$13.2M
Total current assets$450.4M$481.8M$350.6M$272.6M$326.2M
Property, plant and equipment, net$47.9M$45.7M$49M$32.1M$8.32M
Goodwill and intangible assets$710K$930K$1.2M$1.48M$1.75M
Long-term investments$3.04M$3.04M$3.04M$3.04M$780K
Total non-current assets$57.7M$52.2M$54.2M$36.7M$10.9M
Total assets$508.1M$534M$404.7M$309.3M$337M
Accounts payable$17.3M$10M$13.5M$9.39M$2.03M
Short-term debt$2.21M$1.91M$1.68M$2.13M$2.1M
Deferred revenue$13.1M$9.56M$5.66M$2.85M$1.02M
Total current liabilities$65.8M$53.1M$45.9M$35.3M$16.2M
Long-term debt$76.3M$78.3M$77.5M$75.2M$52M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$76.4M$78.7M$78M$77M$53.7M
Capital lease obligations$24.7M$26.9M$26.2M$24M$1.99M
Total liabilities$142.2M$131.8M$124M$112.3M$69.9M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-641.56M-$-545.99M-$-454.57M-$-348.68M-$-261.52M
Accumulated other comprehensive income (loss)$40K$110K$80K-$-10K-$-50K
Total equity$365.9M$402.2M$280.8M$197.1M$267.1M
Total investments$3.04M$3.04M$3.04M$3.04M$780K
Total debt$78.5M$80.3M$79.2M$77.3M$54.1M
Net debt-$-208.02M-$-253.47M-$-178.02M-$-145.32M-$-250.22M
Cash flow statement
20252024202320222021
Net income-$-95.57M-$-91.41M-$-105.9M-$-87.15M-$-59.85M
Depreciation and amortization$6.39M$5.23M$3.81M$2.84M$3.32M
Stock-based compensation$47.6M$31.8M$19.1M$10.3M$3.8M
Change in working capital-$-7.84M-$-47.33M-$-26.16M-$-11.49M-$-4.71M
Accounts receivable-$-900K-$-35.96M-$-33.1M-$-10.81M-$-2.91M
Inventory-$-14.5M-$-17.23M-$-9.75M-$-15.25M-$-6.12M
Accounts payable$6.65M-$-2.15M$5.79M$3.96M$810K
Net cash provided by operating activities-$-48.98M-$-99.21M-$-108M-$-80.38M-$-57.33M
Investments in property, plant and equipment-$-9.36M-$-4.41M-$-25.21M-$-2.65M-$-590K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-9.36M-$-4.41M-$-25.21M-$-2.65M-$-590K
Common stock issued$11.2M$164.5M$161.7M$0.00$172.4M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$11.2M$180.1M$167.8M$3.61M$262.1M
Net change in cash-$-47.22M$76.5M$34.6M-$-79.42M$204.2M
Cash at end of period$289.5M$336.8M$260.3M$225.7M$305.1M
Operating cash flow-$-48.98M-$-99.21M-$-108M-$-80.38M-$-57.33M
Capital expenditure-$-9.36M-$-4.41M-$-25.21M-$-2.65M-$-590K
Free cash flow-$-58.34M-$-103.62M-$-133.21M-$-83.03M-$-57.93M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About PROCEPT BioRobotics Corporation

        PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology. Its flagship product is the AquaBeam Robotic System, a sophisticated, image-guided surgical robot designed for minimally invasive urological procedures. This system primarily facilitates Aquablation therapy, which the company also devised, to alleviate lower urinary tract symptoms in male patients diagnosed with benign prostatic hyperplasia (BPH). As of year-end 2021, PROCEPT BioRobotics had successfully deployed 130 AquaBeam Robotic Systems across the globe, with a significant majority—78 units—located in the United States. Founded in 2007, the corporation maintains its headquarters in Redwood City, California.

        CEO
        Larry L. Wood
        Employees
        888
        Beta
        0.87

        Explore

        Frequently asked questions

        What is the intrinsic value of PROCEPT BioRobotics Corporation (PRCT)?

        PROCEPT BioRobotics Corporation (PRCT) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is PRCT undervalued?

        PRCT trades at a price of $24.70 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.